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Abstract
Purpose: Recently we showed that a number of carboxylated near-infrared fluorescent (NIRF)
cyanine dyes possess strong necrosis avid properties in vitro as well as in different mouse
models of spontaneous and therapy-induced tumor necrosis, indicating their potential use for
cancer diagnostic- and prognostic purposes. In the previous study, the detection of the cyanines
was achieved by whole body optical imaging, a technique that, due to the limited penetration of
near-infrared light, is not suitable for investigations deeper than 1 cm within the human body.
Therefore, in order to facilitate clinical translation, the purpose of the present study was to
generate a necrosis avid cyanine-based NIRF probe that could also be used for single photon
emission computed tomography (SPECT). For this, the necrosis avid NIRF cyanine HQ4 was
radiolabeled with 111indium, via the chelate diethylene triamine pentaacetic acid (DTPA).
Procedures: The necrosis avid properties of the radiotracer [111In]DTPA-HQ4 were examined in vitro
and in vivo in different breast tumor models in mice using SPECT and optical imaging. Moreover,
biodistribution studies were performed to examine the pharmacokinetics of the probe in vivo.
Results: Using optical imaging and radioactivity measurements, in vitro, we showed selective
accumulation of [111In]DTPA-HQ4 in dead cells. Using SPECT and in biodistribution studies, the
necrosis avidity of the radiotracer was confirmed in a 4T1 mouse breast cancer model of
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spontaneous tumor necrosis and in a MCF-7 human breast cancer model of chemotherapy-
induced tumor necrosis.
Conclusions: The radiotracer [111In]DTPA-HQ4 possessed strong and selective necrosis avidity
in vitro and in various mouse models of tumor necrosis in vivo, indicating its potential to be
clinically applied for diagnostic purposes and to monitor anti-cancer treatment efficacy.
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Introduction
Necrosis is a form of cell death characterized by severe cell
swelling, denaturation and coagulation of cytoplasmic proteins,
and disruption of the cell membrane, causing the release of its
intracellular content. Necrotic cell death is irreversible and is
induced by external factors or disease, such as radiation,
trauma, and loss of blood supply, and is also involved in cancer
development and treatment [1, 2]. In the center of most solid
tumors, an area of ischemia and subsequent necrosis develops,
as vascularization cannot keep up with the rapidly growing
tumor mass. The size and growth rate of this necrotic area is
positively correlated with the aggressiveness of cancer and can,
therefore, be used as a diagnostic biomarker of cancer staging
[3–8]. Moreover, anti-cancer treatments like chemotherapy are
utilized to induce cell death, increasing the total amount of
tumor necrosis [9–11]. Thus, agents that specifically bind to
necrotic tumor tissue can contribute to a more accurate disease
diagnosis and can be exploited to predict early treatment
outcome of anti-cancer treatments [12]. To this end, back in
1988, Epstein and colleagues [13] developed so-called tumor
necrosis targeting (TNT) antibodies that are directed towards
nuclear proteins and labeled with radioactive iodine for
imaging and anti-cancer treatment purposes. Likewise, the
photosensitizing agent hypericin has also been shown to
possess necrosis avidity and is currently under investigation
for cancer imaging and treatment purposes [14–17]. However,
there are several drawbacks for the existing agents. Antibodies
are relatively large in size, have long circulation time, could
induce an immune response, and expensive to develop in good
manufacturing practices (GMP) quality, and the photosensi-
tizer hypericin is phototoxic, poorly soluble, and tend to
aggregate rapidly [16, 18, 19]. All these issues hamper the
clinical translation of these compounds [14, 20–22].
Recently, we reported on two near-infrared fluorescent
(NIRF) carboxylated cyanine dyes, HQ5 and IRDye 800CW
(800CW), that also possess strong necrosis avid properties
[23]. Cyanines are, among other dyes, widely used as
fluorescent tags for protein labeling to enable whole body
optical imaging in small animals [24–28]. Although the
mechanism of necrosis avidity is not fully understood, it is
independent of the enhanced permeability and retention (EPR)
effect [23, 29]. On a cellular level, increased retention of the
dye may involve augmented accessibility to cells that have lost
membrane integrity along with an increased affinity to
denatured cytoplasmatic proteins [30–32]. Using whole body
optical imaging in mice, we showed that these cyanines can be
employed to image areas of spontaneous necrosis in solid
tumors and to determine the efficacy of chemotherapy by
monitoring therapy-induced tumor necrosis [23].
Optical imaging is successfully applied in whole body
imaging for small animals and in imaging of superficial
tissues in humans. Optical imaging is based on the detection
of light emitted from agents and/or tags coupled to
biomolecules in living systems. In order to obtain better
tissue penetration, optical imaging often makes use of agents
and tags that emit light in the near-infrared range. However,
even with these compounds, the maximal penetration depth
is limited to a 1-2 centimeters [33, 34]. Although this
relatively small measuring range is sufficient for the
detection of light in small animals, it is not sufficient for
the detection of light in deep tissues such as tumors situated
deep within the human body. Alternatively, nuclear imaging
modalities such as single photon emission computed
tomography (SPECT) and positron emission tomography
(PET) are used clinically to image deep tissues. To enable
SPECT and/or PET for clinical translation, our previously
described necrosis avid NIRF cyanines must be radiolabeled.
Generally, this is achieved by conjugating a targeting moiety
to a chelate that is subsequently labeled with a metal
radionuclide [35–38]. In the present study we employed this
principle to the necrosis avid cyanine HQ4, a close structural
analogue of the recently studied necrosis avid cyanine HQ5
[23]. As HQ5 has two moieties which can be functionalized
by the chelate diethylene triamine pentaacetic acid (DTPA),
we used HQ4, a mono-derived analogue, to avoid scram-
bling of the DTPA molecules or steric hindrance [39]. HQ4
was conjugated to the chelate (DTPA) and subsequently
labeling with 111indium-chloride (111In-Cl3) was performed.
In this study, we investigated the necrosis avidity of
[111In]DTPA-HQ4 in vitro and in vivo in mouse tumor
models of spontaneous and chemotherapy-induced tumor
necrosis using optical imaging and SPECT.
Material and Methods
Compounds
The cyanine dyes, HQ4 carboxylate and HQ4-NHS ester, were
obtained from Ilumicare BV (Rotterdam, The Netherlands).
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Synthesis of HQ4-DTPA
Synthesis of DTPA-polyethylene glycol (PEG)-NH2, DTPA containing
PEG amine link (4,7,10-trioxa-1,13-tridecanediamine), indicated as PEG-
NH2 in the formula (DTPA-PEG-NH2) was synthesized on chloride-trityl
chloride (Cl-TrtCl) resin. Thus, fluorenylmethyloxycarbonyl (Fmoc)-
PEG amine was incorporated on Cl-TrtCl resin (CTC resin) by reacting
3 eq. Fmoc-PEG amine in presence of 6 eq. N,N-diisopropylethylamine
(DIEA) in dichloromethane (DCM) overnight at room temperature (RT).
Final loading was measured by Fmoc quantification and the value
obtained was around 0.8 mmol/g. Fmoc group removal was carried out
with piperidine–dimethylformamide (DMF) (1:5) (1 × 1 min, 2 ×
10 min). Next, the DTPA-(terta-tBu ester)-COOH (2 eq.) was coupled
using N,N′-dipropan-2-ylmethanediimine (DIPCDI) (2 eq.) and
hydroxybenzotriazole (HOBt) (2 eq.) in DMF overnight. After coupling
overnight, the ninhydrin test was negative. Later on, DTPA-(terta-tBu
ester)-CO-NH-PEG-CTC-resin cleavage and deprotectionwas performed
in two steps.DTPA-(terta-tBu ester)-CO-NH-PEG-CTC-resinwas treated
with 1% trifluoroacetic acid (TFA) inDCM10 times for 1min each time.
Excess DCM was removed using vacuum and side chain protecting
groups were removed using 95 % TFA, 2.5 % triisopropylsilane (TIS),
and 2.5 % water. DTPA-CO-NH-PEG-NH2 was precipitated with cold
methyl-tert-butylether (MTBE) after TFA removal under a N2 stream.
The DTPA-CO-NH-PEG-NH2 was dissolved in water and lyophilized to
obtain the final product. The desired DTPA-CO-NH-PEG-NH2 was
85.0 % in yield with a purity of 90.6 % as analyzed by high-
performance liquid chromatography (HPLC) (retention time
2.28 min). HPLC–mass spectrometry (MS), m/z calc.: 523.25 for
C20H37N5O11, Found: 524.5.28 [M+1]+ and matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) analysis found
524.2 [M+1]+546.3 [M+Na].
Synthesis of DTPA-CO-NH-PEG-NH2–HQ4: HQ4-NHS (8.3 ×
10−4 mmol, 1 mg) dissolved in 50 μl of dimethyl sulfoxide
(DMSO) was added to DTPA-CO-NH-PEG-NH2 (2.8 × 10
-3 mmol,
2 mg) dissolved in 200 μl of DMSO containing 5 μl DIEA and
stirred overnight at room temperature. Later on, the complex
DTPA-CO-NH-PEG-HQ4 was purified by reversed phase (RP)-
HPLC. The desired DTPA-PEG-HQ4 was 50.5 % in yield with a
purity of 98 % as analyzed by HPLC (tR 5.34). HPLC-MS, m/z
calc.: 1331.59 for C66H90N8O17S2, Found: 1332.0[M+1]+ and
MALDI-TOF Found 1331.9 [M+1]+ 1353.9 [M+Na].
Cells and Culture Conditions
4T1-luc2 mouse mammary cancer cells (PerkinElmer, Waltham,
MA, USA) and MCF-7 human mammary cancer cells were all
cultured in RPMI-1640 medium (Life Technologies Inc., Carlsbad,
CA, USA) supplemented with 10 % fetal calf serum (FCS; Lonza,
Basel Switzerland), 100 units/ml penicillin, and 50 μg/ml strepto-
mycin (Life Technologies Inc.). All cell lines were cultured in a
humidified incubator at 37 °C and 5 % CO2, monthly checked for
Mycoplasma infection by polymerase chain reaction (PCR) and
checked routinely for morphologic changes.
Dry Ice Dead Cell Assay
In vitro, cell death was studied using a cryo-induced cell death
assay as previously described [40]. In short, 4T1-luc2 cells were
seeded onto 24-well tissue culture plates (Sigma-Aldrich) and
grown until confluent. After discarding the medium, a bar of dry ice
3–5 mm in diameter was applied to the underside of the culture
well for 20 s. Subsequently, the cells were incubated in the dark for
15 min at RT with HQ4 at a concentration of 100 nM. After
incubation, the samples were gently washed with phosphate-
buffered saline (PBS) and subsequently scanned for fluorescence
using the Odyssey Infrared Imager 9120 (LI-COR) and for
radioactivity via phosphor imaging on the Typhoon 9410 imager
(GE Healthcare).
In Vitro Viability Assay
4T1-luc2 cells were plated in a 96-well plate (Costar) in 100 μl
medium at a density of 10,000 cells per well and left over night to
adhere. The next day, the medium was replaced with medium
containing the experimental compounds: HQ4, HQ4-DTPA, HQ5,
and Gambogic acid (GA), three wells per condition. After 24 h, cell
viability was measured using a nonradioactive colorimetric MTS
viability assay (Promega Benelux) according to the manufacturer’s
protocol. Optical absorption was measured at 490 nm with a
Versamax absorbance microplate reader (Molecular Devices).
Animals
Female athymic mice (BALB/c nu/nu, 6 weeks old) were purchased
from Charles River Laboratories (L′Arbresle Cedex, France).
Animals were housed per four to five animals in individually
ventilated cages at 22 °C and 50 % humidity with free access to
food and water and maintained under standard 12 h light/12 h dark
cycles. All surgical and analytical procedures were performed
under isoflurane gas anesthesia (3 % induction, 1.5–2 % mainte-
nance) in 70 % pressurized air and 30 % O2. Animals were
sacrificed by cervical dislocation at the end of the experimental
period.
All animal experiments were assessed for animal health, ethics,
and research and approved by the Animal Welfare Committee of
Leiden University Medical Center, the Netherlands. All mice
received humane care and were kept in compliance with the Code
of Practice Use of Laboratory Animals in Cancer Research
(Inspectie W&V, July 1999).
Subcutaneous Tumor Model
Approximately 1 × 105 4T1-luc2 cells, suspended in 15 μl PBS,
were implanted bilateral and subcutaneously onto the upper back of
nude mice. Tumors were grown until they reached a size of 6–
7 mm in diameter which developed roughly after 1.5–2 weeks of
tumor implantation.
Similarly, 2 × 106 MCF-7 cells, suspended in 15 μl PBS in a 1:1
mixture with 15 μl of Matrigel (BD biosciences, San Jose, CA,
USA), were implanted bilateral and subcutaneously onto the upper
back. Tumors were grown until they reached 6–7 mm diameter,
which developed after approximately 2–3 weeks.
Whole body FLI measurements were performed using the Pearl
Impulse Small Animal Imaging System (LI-COR) and/or IVIS
Spectrum in vivo imaging system (PerkinElmer) several time points
M.A. Stammes et al.: Radiolabeled Necrosis Avid Cyanine for Imaging Cell Death 907
after injection. On the IVIS, an excitation and emission wavelength
of 675 and 720 nm was used for HQ4.
Radiolabeling of HQ4-DTPA and SPECT
To label HQ4-DTPA with 111In-Cl3, it was dissolved in 0.1 M
Hepes (10 μg/100 μl) [41] and 111In-Cl3 (35 MBq; Covidien-
Mallinckrodt, Petten, The Netherlands) was added. After 30 min of
incubation on the shaker, labeling was validated with HPLC (Jasco
Inc., Easton, MD, USA) or thin layer chromatography (TLC). In all
cases, labeling efficacy was 990 %.
To study the specificity of the radiolabeled HQ4-DTPA versus
radiolabeled DTPA in vivo, 10 μg [111In]DTPA-HQ4 (=10 nmol
per mouse) or 10 μg [111In]DTPA was injected i.v. into mice
bearing 4T1-luc2 tumors (n = 3 and 4, respectively). The total
injected dose (ID) in each mouse was determined in a dose-
calibrator (VDC101, Veenstra Instruments, Joure, the Netherlands).
SPECT scans were conducted at several time points post
injection on a three-headed U-SPECT-II gamma camera (MILabs,
Utrecht, The Netherlands) under isoflurane anesthesia for 40 min.
Radioactivity counts from total body scans were acquired using a
0.6-mm mouse pinhole collimator with energy settings at 171 and
245 keV with a window of 20 % and background energy settings of
respectively 4.5 and 3.5 % around the tails of the energy window
[42]. Subsequently, the image was reconstructed using 20 POSEM
iterations with four subsets, 3D gauss 1 mm (FWHM) filtering, a
0.2-mm voxel size, and with decay and scatter corrections
integrated into the reconstruction [43]. Images were generated and
analyzed using PMOD software. In vivo SPECT was followed by
in vivo fluorescence imaging on the Pearl Impulse Small Animal
Imaging System (LI-COR).
After the last imaging time point, mice were sacrificed and
several tissues were excised, weighed, and counted for radioactivity
(Wizard2 2470 automatic gamma scintillation counter, Perkin
Elmer, USA) to determine the percentage of the injected dose per
gram (%ID/g). The %ID/g was calculated as follows: (((MBq
measured in tissue/injected dose) × 100 %) / weight of tissue).
Chemotherapy of MCF-7 Tumors
In two groups of mice (n = 5), 2 weeks after tumor implantation the
mice received either an intraperitoneal (i.p.) injection of cyclophos-
phamide (265 mg/kg; Baxter BV, Utrecht, The Netherlands) [44] or
remained untreated. After 72 h, all animals received an i.v. injection
of radiolabeled HQ4-DTPA. SPECT scans were conducted 24 h
later, followed by whole body FLI. After the last imaging time
point, mice were sacrificed, several tissues were excised, weighted,
and counted for radioactivity.
Ex Vivo Tumor Imaging
Ex vivo tumor imaging was performed to visualize the distribution
of the probe in the tumor. Images were obtained for FLI (Odyssey
Infrared Imager 9120 (LI-COR)) and for radioactivity via phosphor
imaging (Typhoon 9410 imager (GE Healthcare) and ImageQuant
TL software). For phosphor imaging, the tumors were manually
sliced in sagittal sections and placed o/n on a phosphor screen.
Histological Procedures
The tumors collected for histological analysis were fixed in 4 %
formaldehyde and embedded in paraffin. Five micrometer sections
were prepared and FLI was performed using the Odyssey Infrared
Imager (LI-COR). Afterwards, the sections were subjected to TdT-
mediated dUTP Nick-End Labeling (TUNEL) staining (Promega,
Madison, WI, USA) to validate accumulation of the NIRF probes in
necrotic cells.
Statistical Analysis
All statistical analysis was performed using Prism software
(GraphPad). For repeated measures, a Student’s t test was used in
all cases. P G 0.05 was considered significant, and all error bars
represent mean SEM.
Results
We selected the necrosis avid cyanine HQ4, instead of HQ5,
to perform radiolabeling and further in vitro and in vivo
investigations to demonstrate its potential clinical transla-
tion. The choice for HQ4 was based on the number of
functionalized moieties present in the cyanine molecules,
which is one in the case of HQ4 and two in the case of HQ5
(see Online Resource 1, suppl. Fig. 1a). Furthermore, as
shown in online Resource 1, suppl. Fig. 1b, HQ4 showed
slightly higher necrosis avid properties in our dry ice dead
cell assay than HQ5. The fluorescent signal intensity,
obtained from the area of cell death caused by freezing,
was over the whole dose range (1–100 nM) 2.8 (+/−1.0)-fold
higher for HQ4 as compared to HQ5.
A HQ4-DTPA hybrid complex was synthesized by
covalent coupling via conjugation with a polyethylene
glycol (PEG) linker (Fig. 1). Reversed-phase chromatogra-
phy showed a clear peak indicating the high grade of purity
(98 %) of this conjugate. Mass spectrometric analyses of
HQ4-DTPA further showed the expected molecular weight
(calc.: 1331.59 for C66H90N8O17S2 and MALDI-TOF found
1332.4 [M+1]+ 1354.6 [M+Na]), indicating the high grade
of purity of this conjugate (see Online Resource 1, suppl.
Fig. 2). Lastly, the HQ4-DTPA conjugate was labeled with
111In-Cl3 with a labeling efficiency of 990 % (data not
shown).
In Vitro Viability Assay
Using the MTS cell toxicity assay, the acute in vitro toxicity
of the cyanine dyes HQ4, HQ4-DTPA, and HQ5 were
examined in 24 h cultures of 4T1 breast cancer cell and
compared with the cytotoxic compound GA. In the dose
range of 0–20 μM, none of the cyanine compounds affected
cell viability. GA, however, dose dependently induced cell
death with an IC50 of around 6 μM (see Online Resource 1,
suppl. Fig. 3).
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Fig. 1 Chemical and structural characteristics of HQ4-DTPA. Chemical structure of HQ4-DTPA. λabs = absorbance
wavelength; λem = emission wavelength.
Fig. 2 In vitro necrosis avid properties of [111In]DTPA-HQ4 by fluorescence and radioactivity measurements. a Necrotic cell
death in confluent monolayers of 4T1 mouse breast cancer cells was induced by applying dry ice to the underside of the culture
well. Cells were subsequently incubated for 15 min with one of the following: HQ4, HQ4-DTPA, [111In]DTPA-HQ4, [111In]DTPA,
or 111In-Cl3 (100 nM, 10 μg). After subsequent washing with PBS, cells were imaged either for fluorescence (FLI, upper panel) or
for radioactivity (RA, lower panel). NL = not labeled. b Calculated signal-to-background (S/B) ratio (FLI and RA) of the different
compounds obtained from the dry ice assay. The S/B ratio was defined as the signal intensity obtained from the area of dead
cells in the center of the well divided by the signal intensity obtained from an area of living cells of the same size in the
periphery.
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In Vitro Necrosis Targeting Properties of
[111In]DTPA-HQ4
The dry ice dead cell assay was performed to examine the
necrosis avid properties of the entire conjugate
[111In]DTPA-HQ4 and the individual components, HQ4
and HQ4-DTPA, respectively, in vitro. HQ4, HQ4-DTPA,
and [111In]DTPA-HQ4 all strongly accumulated in the area
of dead cells, as shown by fluorescence imaging (Fig. 2a). In
addition, radioactive signal was obtained in areas of dead
cells only when incubated with [111In]DTPA-HQ4. In
contrast, neither [111In]DTPA nor free 111In-Cl3 accumulated
in the dead cells area, as indicated by RA measurements.
Fig. 2b shows quantifications of the fluorescent and
radioactive signal-to-background (S/B) (dead cells vs living
cells area) ratios for the five different compounds tested
confirming that [111In]DTPA-HQ4 retains fluorescence and
radioactivity, as well as necrosis avidity with a S/B ratio of
11.1 and 2.4, respectively.
Necrosis Targeting Properties
of [111In]DTPA-HQ4 in a 4T1 Mouse Tumor
Model of Spontaneous Necrosis
The necrosis targeting properties of [111In]DTPA-HQ4 were
evaluated in subcutaneous 4T1 breast tumor bearing mice,
using SPECT and optical imaging. [111In]DTPA-HQ4
(10 nmol, 30–35 MBq) was injected intravenously (i.v.)
into the tumor bearing mice, and in vivo SPECT and optical
images were obtained 6, 24, 48, and 72 h, post injection
(Fig. 3a, b). An increased retention of [111In]DTPA-HQ4 in
the tumors and in the metabolizing organs was observed
over time with both optical imaging and SPECT.
To further assess the biodistribution of [111In]DTPA-HQ4
in different organs, mice (n = 3) were sacrificed at each time
point. Subsequently, radioactivity in various organs and body
fluids was quantified (Fig. 3c). The measured radioactivity
across different time points confirmed accumulation of
radioactivity in the tumors (4.8 %ID/w), liver (3.3 %ID/w),
and the kidneys (7.6 %ID/w) at 72 h post injection. Finally,
histological examination of the 4T1 tumors confirmed the
presence of a large necrotic core (Fig. 3d).
Similarly, the biodistribution of the radiolabeled chelate
[111In]DTPA was examined in 4T1 tumor bearing mice 24 h
after i.v. injection of [111In]DTPA (10 μg, 30–35 MBq).
Mice (n = 4) were euthanized and the internal organs and
body fluids were removed to quantify remaining radioactiv-
ity (see Online Resource 1, suppl. Fig. 4a). Greatest
accumulation of radioactivity was observed in the kidneys
(5.0 %ID/w) and only relatively low values of radioactivity
could be measured in other organs, body fluids, and tumors
(tumors 0.5 %ID/w, liver 0.6 %ID/w).
Supplementary Fig. 4b, Online Resource 1, shows the
measured amount of radioactivity in the mouse corpus at
different time points after injection of [111In]DTPA-HQ4 or
[111In]DTPA, expressed as the percentage of the total
injected doses (%ID). It was found that 24 and 48 h after
injection of [111In]DTPA-HQ4, respectively, 38 and 35 % of
total injected dose was retained in the body, whereas this
was only 10 and 8 %, for [111In]DTPA.
SPECT and Optical Imaging of [111In]DTPA-HQ4
in a MCF-7 Mouse Model
of Chemotherapy-Induced Tumor Necrosis
Using SPECT and optical imaging, we examined whether
[111In]DTPA-HQ4 could be employed to monitor
chemotherapy-induced tumor necrosis. For this, MCF-7
tumor bearing mice were treated with a single i.p. injection
of cyclophosphamide (265 mg/kg) [44], followed by an i.v.
injection of [111In]DTPA-HQ4 (10 nmol, 30–35 MBq) 72 h
later. Twenty-four hours after injection of [111In]DTPA-
HQ4, whole body optical images and SPECT were obtained
to assess its biodistribution. Both optical imaging and
SPECT showed accumulation of [111In]DTPA-HQ4 in
cyclophosphamide-treated tumors as compared to untreated
tumors (Fig. 4a, b). Fig. 4c shows quantification of the
fluorescent signals obtained from the tumors, 24 h after
probe injection. A significant increase in tumor fluorescent
signal intensity was observed in mice that were treated with
chemotherapy as compared to untreated controls (ratio =
1.8:1.0, p = 0.0011).
Biodistribution study based on quantification of radioac-
tivity in various organs further demonstrated higher amount
of radioactivity in chemotherapy-treated tumors compared to
untreated controls. The average %ID/w was 1.85 for the
control tumors vs 4.02 for the chemo-treated tumors
(Fig. 4d). In addition, a significantly higher amount (1.4-
fold) of radioactivity was observed in left kidneys of the
chemotherapy-treated mice as compared to controls.
Finally, tumors of chemotherapy-treated and control mice,
which were injected with [111In]DTPA-HQ4 (10 nmol, 30–
35 MBq), were dissected and cut in half to perform ex vivo
fluorescence and radioactivity analysis. In addition, the
opposite half of the tumor was processed for paraffin
embedding and histological analyses. As shown in Fig. 5, the
TUNEL-stained section of the untreated control tumor showed
very little necrotic tissue, whereas the chemotherapy-treated
tumor contained a large area of necrotic tissue (brown staining).
Notably, the TUNEL staining showed co-localization with
both fluorescence and radioactivity signals in tumors,
confirming the specific increased necrosis retention property
of [111In]DTPA-HQ4. For comparison, all the settings used for
the different images are similar.
Discussion
Over the last two decades, several attempts have been made to
exploit disease and/or therapy-induced tumor necrosis as a
diagnostic and/or prognostic biomarker of disease and to utilize
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necrotic tissue as a target for drug delivery. The existing
necrosis imaging agents can be divided into two different
groups: (non-) specific CT and MR contrast agents to enhance
the natural signal and the other group consists out of mostly
radiolabeled necrosis avid contrast agents (NACAs) that
specifically target necrotic tissue. The latter can also be
Fig. 3 Optical imaging, SPECT, and biodistribution of [111In]DTPA-HQ4 in 4T1 breast tumor bearing mice. a Whole body FLI
(coronal view) obtained 6–72 h after tail vein injection of [111In]DTPA-HQ4 (10 nmol, 30–35 MBq). The white light image (WL)
indicates the position of the mouse in the Pearl imager, from a dorsal point of view (T = tumor). The same device settings were
applied to all FLI, rendering comparison between the different images possible. b Whole body SPECT images (sagittal view)
obtained 6–72 h after tail vein injection of [111In]DTPA-HQ4 (10 nmol, 30–35 MBq). The white light image (WL) indicates the
position of the mouse from a sagittal point of view, in the SPECT (RA); T = tumor, L = liver, K = kidney, and I = intestine. Arrows
indicate the tumor. c Biodistribution of [111In]DTPA-HQ4 in 4T1 tumor bearing mice. Six, 24, 48, and 72 h after probe injection,
mice (n = 3 per time point) were sacrificed and the organs, body fluids, and tumors were dissected, weighed, and measured for
radioactivity in a gamma counter. At each time point, the amount of radioactivity in the organs is expressed as percentage of
the injected dose divided by body weight (%ID/w). d TUNEL-stained histological section of a representative 4T1 mouse breast
tumor showing a large area of necrosis (brown).
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employed for therapeutic purposes, e.g., when radiolabeled
with Iodine-131 [2–10, 13, 15, 23, 45–49]. It is expected that
the non-specific necrosis contrast agents will fall into abeyance
when compounds with high necrosis specificity become
clinically available. However, thus far, only the Iodine-131
conjugated Tumor Necrosis Targeting monoclonal antibody
(TNT-3), licensed by Peregrine Pharmaceuticals reached the
clinical trials for therapeutic use [13, 21]. This antibody, under
the brand name CotaraTM, has been examined in clinical trials
for treatment of Glioblastoma Multiforma. However, although
encouraging results have been published on the website of the
manufacturer in December 2012, no follow-up studies have
been reported since [50]. In addition, the necrosis avid
photosensitizer hypericin, under the brand name Oncocidia,
is also under investigation to enter clinical trials [14, 51, 52].
Although proof of concept has been shown for both
approaches, both compounds, as mentioned earlier, suffer
from major drawbacks which hampers their clinical
translation.
To overcome the limitations associated with the size and
possible immunogenicity of antibodies, the phototoxicity,
problems with solubility and ability to aggregate, a simple,
injectable and non-toxic agent that displays specific necrosis
avidity is required. Recently, we demonstrated that two non-
toxic constituents of the group of NIRF cyanine dyes,
IRDye800CW and HQ5 carboxylate, the former being com-
monly used as an optical probe for biomolecular labeling [53,
54], display strong and specific necrosis avid properties in vitro
as well as in tumor bearingmice [23]. In this study, the increased
retention of NIRF cyanine dyes in tumor necrosis was examined
using whole body fluorescence imaging. Although whole body
optical imaging is suitable for use in small animals, it is often
insufficient for assessments of deep tissues in the human body,
due to the limited tissue penetration depth of NIRF light. In
order to seek for potential clinical applications for our newly
discovered necrosis avid cyanines, we examined the possibility
to radiolabel it for in vivo nuclear imaging by conjugating to a
chelator [55, 56]. To render HQ4 applicable for SPECT, we first
Fig. 4 Optical imaging, SPECT, and biodistribution of [111In]DTPA-HQ4 in chemotherapy-treated MCF-7 tumor bearing mice.
Representative whole body FLI (coronal) and SPECT (MIP) images of MCF-7 tumor bearing a control and b cyclophosphamide-
treated mice. Mice were injected with [111In]DTPA-HQ4 (10 nmol, 30–35 MBq) 72 h after injection with chemotherapy. Whole
body FLI and SPECT were acquired 24 h after probe injection. c Mean FL signal intensity obtained from the tumors of control
and chemotherapy-treated mice (n = 5, two tumors per mouse), 24 h after injection of [111In]DTPA-HQ4. d Biodistribution of
[111In]DTPA-HQ4 in MCF-7 tumor bearing mice. Mice were injected with [111In]DTPA-HQ4 72 h after chemo-treatment and were
sacrificed 24 h later, and the organs, body fluids and tumors were dissected, weighed, and measured for radioactivity in a
gamma counter. The amount of radioactivity in the organs is expressed as percentage of the injected dose divided by the
weight (%ID/w).
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conjugated HQ4 to the chelate DTPA with a linker molecule,
and subsequently radiolabeled with 111In-Cl3. Following the
synthesis and purification procedures, purity of 98 % was
achieved. Thus, we created a molecule that targets necrosis and
can be imaged using both NIRF and SPECT.
We demonstrated in vitro that [111In]DTPA-HQ4, like
unconjugated HQ4, appears to specifically bind to dead cells
after washing. Our findings, in the dry ice assay, show that
the specificity of [111In]DTPA-HQ4 for necrotic cells was
solely due to the presence of the HQ4 molecule, as the
radiolabeled chelate [111In]DTPA alone and free 111In-Cl3
did not show to bind to the dead cells. Although DTPA
conjugation is likely to change the chemical and physico-
chemical properties of HQ4, for example by increasing its
overall hydrophylicity [57], it retained its necrosis avid- and
fluorescent properties. We observed a clear difference in the
signal-to-background (S/B) ratio of [111In]DTPA-HQ4 be-
tween fluorescence- and radioactivity measurements. The
reason for this discrepancy is unclear, but may involve
environmental conditions that specifically affect the fluores-
cent properties of the molecule. Previously, Jiskoot et. al
[58] reviewed the fluorescence properties of extrinsic dyes,
which are strongly influenced by their environment (hydro-
philic/hydrophobic or differences in pH) and/or by interac-
tions with proteins. Such factors may also influence
fluorescence signal intensity of HQ4 in an environment of
living cells compared to in an environment of dead cells.
However, such environmental-dependent signal intensity
influences will not occur when a radiolabel, offering a
quantitative readout, is utilized. Nevertheless, the observed
S/B ratio of 2.5, obtained with radioactivity measurements,
is theoretically sufficient for clinical translation [59].
Additional studies that determine the relationship between
time, probe concentration, and S/B ratio could help to
optimize the sensitivity of the measurements.
Furthermore, none of the cyanine dyes, including HQ4-
DTPA, showed any acute in vitro toxicity in cultures of 4T1
cells. Even at the highest concentration of 20 μM (during 24 h),
which is 200-fold higher compared to the concentration used to
image dead cells in vitro, cell viability remained unaffected.
Collectively, our in vitro study revealed that DTPA
conjugation is not deleterious to the necrosis avid properties
of HQ4 and the lack of toxicity encouraging further studies
with the aim of its clinical translation. Further investigations
are warranted concerning the mechanism of interaction of
the DTPA conjugated cyanine to specific proteins in necrotic
cells. In the paper of Xie et al.[23], we showed that HQ5, a
close cyanine analogue of HQ4, specifically accumulated in
necrotic cells and not in apoptotic cells. Moreover, we have
shown that HQ5 does not co-localize with F4/80 macro-
phage staining in an around the tumor, indicative of
inflammation. Nevertheless, we did not yet examine these
specific mechanistic properties for HQ4.
Using in vivo whole body optical imaging, SPECT, and
ex vivo analysis, we confirmed the observed in vitro necrosis
avid properties of [111In]DTPA-HQ4 in two tumor models: 4T1
mouse breast cancer tumor model of spontaneous necrosis and
MCF-7 human breast cancer tumor model of chemotherapy-
induced tumor necrosis. MCF-7 tumor model was selected to
assess chemotherapy-induced necrosis due to its slow growth
kinetics. MCF-7 tumor cells have a population doubling time
(PDT) of approximately 38 h in vitro [60], thus representing a
slow-growing tumor. This is in contrast to 4T1-cells, PDT
+/−12 h [61], which develop necrotic cores spontaneously, and
to EL4-cells, PDT +/−17 h [62], used in the previous paper [23].
Since MCF-7 cells hardly develop spontaneous necrosis during
their growth, necrosis induced by chemotherapy is more evident
and can be determined with higher accuracy. Moreover, MCF-7
cells are of human origin, which may also more accurately
mimic the clinical situation [63].
In both mouse tumor models, the acquired optical imaging
and SPECT results over time provided information on the
pharmacokinetic profile of [111In]DTPA-HQ4. In the model of
spontaneous tumor necrosis, necrotic areas in the tumor were
clearly delineated using optical imaging and SPECT. No clear
specific tissue interactions could be detected 6 h after injection,
probably due to high quantities of unbound circulating probe in
the blood at this early time point. The amount of radioactivity
that retained in the 4T1 tumors remained approximately equal
over time, while, it declined in most organs and body fluids,
resulting in a relative increase in tumor signal intensity inside the
tumor at later time points. In the chemotherapy-induced tumor
necrosis model, the specific targeting of [111In]DTPA-HQ4 to
necrotic areas of MCF-7 tumors was confirmed histologically
using TUNEL staining. In this model we also observed that the
Fig. 5 Histological and ex vivo analysis of [111In]DTPA-HQ4
injected control and chemotherapy-treated MCF-7 tumors.
Tumors were dissected 24 h after probe injection and were
subsequently cut in half for ex vivo FLI and RA analysis. The
opposite half of the tumor was used for paraffin embedding
and TUNEL staining (brown indicates the area of necrosis).
FLI = fluorescence imaging.
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kidneys of the chemotherapy-treated mice retained more
radioactivity than in untreated mice. The reason for this is
unknown, but it might be speculated that some necrosis may
develop due to cyclophosphamide-induced renal oxidative stress
which leads to perioxidative damage to the kidneys [64].
Finally, we compared the biodistribution and clearance
rate of [111In]DTPA-HQ4 with that of the free labeled
chelate ([111In]DTPA). We observed that both the
biodistribution and the excretion rate of the two compounds
were vastly different. Twenty-four hours after probe injec-
tion, [111In]DTPA was mainly retained in the kidneys and
could hardly be detected in other organs or in the tumors,
confirming our in vitro findings of a lack of tumor necrosis
specificity. The observed accumulation of [111In]DTPA in
the kidneys confirms findings of Boswell and colleagues
[65] who also reported predominant clearance of this
hydrophilic compound via this excretion route. Moreover,
not only the organ distribution of these two compounds was
dissimilar, the clearance rate of [111In]DTPA was about 8-
fold faster than that of [111In]DTPA-HQ4. Combined, these
findings indicate that both the pharmacokinetics and the
tissue targeting properties of [111In]DTPA-HQ4 and
[111In]DTPA are largely different and strengthen the notion
that the cyanine HQ4 governs the overall necrosis avid
properties of the [111In]DTPA-HQ4 molecule.
Conclusion
In summary, we successfully yielded a new necrosis avid
SPECT radiotracer by conjugating the necrosis avid cyanine
HQ4 to DTPA, followed by radiolabeling with 111In-Cl3.
We showed that, after DTPA conjugation, this newly
synthesized radiotracer retained its specific necrosis
targeting properties in vitro and in vivo in mouse models
of spontaneous and therapy-induced tumor necrosis. The
advantages of the small molecule [111In]DTPA-HQ4 include
the following: high water solubility, NIRF property that
enables deep penetration into tissues, lack of phototoxicity,
and low production costs. Therefore, the necrosis avid
radiotracer [111In]DTPA-HQ4 has the potential to be
clinically translated for diagnostic-prognostic purposes and
to predict early treatment outcome of anti-cancer treatments.
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